Edition:
United Kingdom

Novelion Therapeutics Inc (NVLN.OQ)

NVLN.OQ on NASDAQ Stock Exchange Global Select Market

1.34USD
15 Feb 2019
Change (% chg)

$-0.02 (-1.47%)
Prev Close
$1.36
Open
$1.35
Day's High
$1.39
Day's Low
$1.33
Volume
37,313
Avg. Vol
326,274
52-wk High
$5.28
52-wk Low
$0.70

Latest Key Developments (Source: Significant Developments)

Healthcare Value Capital, On Dec 3, On Behalf Of Healthcare Value Partners, Sent Letter To Novelion Therapeutics Board
Monday, 3 Dec 2018 

Dec 3 (Reuters) - Healthcare Value Capital: :HEALTHCARE VALUE CAPITAL - ON DECEMBER 3, HEALTHCARE VALUE CAPITAL, ON BEHALF OF HEALTHCARE VALUE PARTNERS, SENT LETTER TO NOVELION THERAPEUTICS BOARD.HEALTHCARE VALUE CAPITAL SAYS IN LETTER, EXPECT NOVELION THERAPEUTICS TO FAITHFULLY AND THOROUGHLY EXPLORE ALL STRATEGIC ALTERNATIVES - SEC FILING.  Full Article

Highbridge Capital Management Reports 5 Pct Stake In Novelion Therapeutics As Of Nov 19-SEC Filing
Thursday, 29 Nov 2018 

Nov 29 (Reuters) - Novelion Therapeutics Inc ::HIGHBRIDGE CAPITAL MANAGEMENT LLC REPORTS 5.0 PERCENT STAKE IN NOVELION THERAPEUTICS INC AS OF NOV 19 - SEC FILING.  Full Article

Novelion General Counsel Benjamin Harshbarger Appointed As Interim CEO
Tuesday, 20 Nov 2018 

Nov 20 (Reuters) - Novelion Therapeutics Inc ::NOVELION THERAPEUTICS INC - NOVELION GENERAL COUNSEL BENJAMIN HARSHBARGER APPOINTED AS INTERIM CHIEF EXECUTIVE OFFICER.NOVELION - JEFFREY HACKMAN RESIGNED AS INTERIM CEO TO PURSUE ANOTHER OPPORTUNITY, WILL STAY WITH CO IN A TRANSITIONAL ROLE UNTIL NOVEMBER 30, 2018..  Full Article

Sarissa Capital Management Lp Reports 4.6 pct Stake In Novelion Therapeutics Inc As Of November 8
Friday, 9 Nov 2018 

Nov 9 (Reuters) - :SARISSA CAPITAL MANAGEMENT LP REPORTS 4.6 PERCENT STAKE IN NOVELION THERAPEUTICS INC AS OF NOVEMBER 8, 2018 - SEC FILING.SARISSA CAPITAL MANAGEMENT LP - HAD PREVIOSULY REPORTED 9.86 PERCENT STAKE IN NOVELION THERAPEUTICS INC AS OF MARCH 15, 2018.SARISSA CAPITAL MANAGEMENT LP-ON NOV 8, UNIT OF NOVELION THERAPEUTICS REPAID TO SARISSA FUNDS ALL AMOUNTS OUTSTANDING UNDER LOAN AGREEMENT.  Full Article

Novelion Therapeutics subsidiary enters into term loan agreement and Novelion provides business update
Thursday, 8 Nov 2018 

Nov 8 (Reuters) - Novelion Therapeutics Inc ::NOVELION THERAPEUTICS SUBSIDIARY ENTERS INTO TERM LOAN AGREEMENT AND NOVELION PROVIDES BUSINESS UPDATE.NOVELION THERAPEUTICS INC - FINANCIAL ADVISORS RETAINED TO ADVISE ON STRATEGIC PROCESS AND CAPITAL STRUCTURE REVIEW.NOVELION THERAPEUTICS - EXPECTS TO ACHIEVE POSITIVE CASH FLOW AT AEGERION LEVEL BY 2Q 2019 ON FULL-YEAR NET PRODUCT SALES OF BETWEEN $145 AND $160 MILLION.NOVELION THERAPEUTICS - EXPECTS TO ACHIEVE POSITIVE CASH FLOW AT AEGERION LEVEL BY 2Q 2019 ON FULL-YEAR NET PRODUCT SALES OF BETWEEN $145 AND $160 MILLION.NOVELION THERAPEUTICS INC - EXPECTS TOTAL NET PRODUCT SALES IN 2018 TO BE BETWEEN $130 AND $140 MILLION.NOVELION - FACILITY CONSISTS $50 MILLION NEW SECURED FIRST LIEN TERM LOANS FUNDED TO AEGERION IN CASH.NOVELION THERAPEUTICS INC - EXPECTS TOTAL NET PRODUCT SALES IN 2019 TO BE BETWEEN $145 AND $160 MILLION.NOVELION - FACILITY CONSISTS $22.5 MILLION NEW SECURED TERM LOANS USED TO RETIRE EQUAL AMOUNT OF AEGERION'S 2% CONVERTIBLE NOTES DUE AUG. 2019.NOVELION - CO AND AEGERION ANTICIPATED TO HAVE ABOUT $15.7 MILLION & $37.5 MILLION, RESPECTIVELY, OF CASH AS OF NOV. 8.  Full Article

Novelion Therapeutics Reports Qtrly Net Loss Per Common Share-$1.67
Tuesday, 7 Aug 2018 

Aug 7 (Reuters) - Novelion Therapeutics Inc ::NOVELION THERAPEUTICS REPORTS SECOND QUARTER 2018 FINANCIAL RESULTS.Q2 REVENUE $31.9 MILLION VERSUS $40.9 MILLION.QTRLY NET LOSS PER COMMON SHARE-BASIC AND DILUTED $1.67.QTRLY LOSS PER SHARE $1.67.  Full Article

Novelion Therapeutics Reports Quarterly Net Loss Per Share Of $1.76
Thursday, 10 May 2018 

May 10 (Reuters) - Novelion Therapeutics Inc ::NOVELION THERAPEUTICS REPORTS FIRST QUARTER 2018 FINANCIAL RESULTS.Q1 REVENUE $27.5 MILLION VERSUS $30 MILLION.QUARTERLY NET LOSS PER SHARE $1.76.  Full Article

Novelion Therapeutics Announces Cost Reduction Plans, Capital Structure Review
Wednesday, 24 Jan 2018 

Jan 24 (Reuters) - Novelion Therapeutics Inc ::NOVELION THERAPEUTICS ANNOUNCES COST REDUCTION PLANS AND CAPITAL STRUCTURE REVIEW.NOVELION THERAPEUTICS -ANNOUNCED COST REDUCTION PLANS AS IT MANAGES CASH RESOURCES, EFFECTS OF DELAY & UNCERTAINTY OF SETTLEMENT OF UNIT WITH DOJ, SEC.NOVELION THERAPEUTICS - IN ADDITION TO WORKFORCE AND OTHER COST REDUCTIONS, PURSUING LICENSING OPPORTUNITIES FOR ITS ZURETINOL DRUG CANDIDATE.  Full Article

Edgepoint Investment Group Reports 10.6 Pct Passive Stake In Novelion Therapeutics
Friday, 8 Dec 2017 

Dec 8 (Reuters) - Novelion Therapeutics Inc ::EDGEPOINT INVESTMENT GROUP INC REPORTS 10.6 PERCENT PASSIVE STAKE IN NOVELION THERAPEUTICS INC AS OF NOVEMBER 30 - SEC FILING.  Full Article

Novelion Therapeutics Appoints Michael Price As CFO
Monday, 4 Dec 2017 

Dec 4 (Reuters) - Novelion Therapeutics Inc ::NOVELION THERAPEUTICS APPOINTS MICHAEL PRICE AS SENIOR VICE PRESIDENT AND CHIEF FINANCIAL OFFICER.NOVELION THERAPEUTICS INC - ‍GREGORY PERRY HAS RESIGNED AS CFO TO PURSUE OTHER OPPORTUNITIES, AND WILL REMAIN WITH COMPANY UNTIL DECEMBER 31, 2017​.NOVELION THERAPEUTICS INC - ‍APPOINTS MICHAEL PRICE AS SENIOR VICE PRESIDENT AND CHIEF FINANCIAL OFFICER, EFFECTIVE DECEMBER 4, 2017​.  Full Article